Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00183339 · ClinicalTrials.gov registry record · Phase 2

Early Intervention With Fluoxetine in Autism

A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 2
Development phase
18
Enrollment target

NCT00183339 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00183339, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 2
Development phase
18 participants
Enrollment target

Study Summary

This study is a pilot study to evaluate the feasibility and safety of conducting a year long, double-blind, placebo-controlled trial of fluoxetine in pre-school children to enhance developmental processes in core areas impacted by autism.

Interventions

  • DRUG Placebo
  • DRUG Fluoxetine

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2005-07
Est. Completion 2008-02
Phase Phase 2

What the Registry Record Tells You About NCT00183339

The ClinicalTrials.gov registry entry for NCT00183339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00183339 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00183339 about?

NCT00183339 is a clinical study titled "Early Intervention With Fluoxetine in Autism". This study is a pilot study to evaluate the feasibility and safety of conducting a year long, double-blind, placebo-controlled trial of fluoxetine in pre-school children to enhance developmental processes in core areas impacted by autism.

What is the current status of trial NCT00183339?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2005-07. Estimated completion is 2008-02.

What interventions are being tested in trial NCT00183339?

The interventions under investigation include: Placebo (DRUG), Fluoxetine (DRUG).

Who is sponsoring clinical trial NCT00183339?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.